Abstract:Experimental Biology and Medicine, Ahead of Print. In recent years, with the increase of air pollution, smoking, aging, and respiratory infection, the incidence rate and mortality of lung diseases are increasing annually, which has become a major hazard to human health. N6-methyladenosine (m6A) RNA methylation is the most abundant modifications in eukaryotes, and such modified RNA can be specifically recognized and combined by m6A recognition proteins and then mediate RNA splicing, maturation, enucleation, degradation, and translation. More and more studies have revealed that the m6A modification is involved in the pathogenesis and development of some diseases; however, the mechanisms of m6A in lung diseases are poorly understood. In this review, we summarize the latest progress in the biological function of m6A modifications in lung diseases and discuss the potential therapeutic and prognostic strategies. The dysregulation of global m6A levels and m6A regulators may affect the occurrence and development of asthma, chronic obstructive pulmonary disease, lung cancer, and other lung diseases through inflammation and immune function. In lung cancer, this modification has an important impact on malignant cell proliferation, migration, invasion, and drug resistance. In addition, abnormally changed m6A-modified proteins in lung cancer tissue samples and circulating tumor cells (CTCs) may be used as diagnostic and prognostic markers of lung cancer. Models composed of multiple m6A regulators can be used to evaluate the risk prediction or prognosis of asthma and pulmonary fibrosis. In general, the in-depth study of m6A modifications is a frontier direction in disease research. It provides novel insights for understanding of the molecular mechanisms underlying disease occurrence, development, and drug resistance, as well as for the development of effective novel therapeutics.

m 6A methylation modification and lung cancer

The emerging roles of N6-methyladenosine RNA methylation in human cancers

The Emerging Molecular Mechanism of M6a Modulators in Tumorigenesis and Cancer Progression

The momentous role of N6-methyladenosine in lung cancer

Research Advances of M6a Modification in Lung Cancer

Emerging role of N6-methyladenosine RNA methylation in lung diseases

The Implications of N6-methyladenosine (m6a) Modification in Esophageal Carcinoma

The Roles of M6a RNA Modifiers in Human Cancer

N<SUP>6</SUP>-methyladenosine as a biological and clinical determinant in colorectal cancer: progression and future direction

N6-methyladenosine Modification: an Important Player in the Tumor Immune Microenvironment.

The Potential Value of M6a RNA Methylation in the Development of Cancers Focus on Malignant Glioma

The roles of m<SUP>6</SUP>A RNA modifiers in human cancer

m6A RNA Methylation Regulators Act as Potential Prognostic Biomarkers in Lung Adenocarcinoma

Function of N6-Methyladenosine Modification in Tumors

N 6 ‐methyladenosine Steers RNA Metabolism and Regulation in Cancer

RNA M6a Modification in Cancers: Molecular Mechanisms and Potential Clinical Applications.

The Evolving Landscape of N6-methyladenosine Modification in the Tumor Microenvironment.

N6-Methyladenosine RNA Modification in the Tumor Immune Microenvironment: Novel Implications for Immunotherapy

[Research progress on the role of N6-methyladenosine methylation in the pathogenesis and development of respiratory diseases]

Progression of m 6 A in the tumor microenvironment: hypoxia, immune and metabolic reprogramming

N6-Methyladenosine methylation modification in breast cancer: current insights